By contrast, several pathological mechanisms underlying AMD development in patients without OSA, such as changes in the extracellular matrix, changes in Bruch’s membrane composition and permeability, or oxidative mitochondrial damage due to aging or genetic factors, may be partially responsible for their inferior fluid resorption after anti-VEGF treatment [27]. This evidence concerns the gene VEGFA and age-related macular degeneration.